A comprehensive new systematic review published in The Journal of Nutrition provides the latest evidence that large-scale food fortification is a highly cost-effective intervention for reducing global ...

Introduction The clinical management of Obstructive Hypertrophic Cardiomyopathy remains challenging, and the phase III EXPLORER-HCM trial has demonstrated that the novel cardiac myosin inhibitor ...

Large-Scale Pharmacogenomics Analysis of Patients With Cancer Within the 100,000 Genomes Project Combining Whole-Genome Sequencing and Medical Records to Inform Clinical Practice SOC was dominated by ...

Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial We derived disease progression and therapy ...

Usual care provided 9.59 QALYs at a lifetime cost of $222,300, diet and exercise yielded 9.75 QALYs for $226,300, and semaglutide offered 10.48 QALYs at $273,500, with tirzepatide providing 10.68 ...

A new technology for management of diabetes is cost-effective for patients in the US with type 1 diabetes compared with traditional treatments. Objectives: Advances in diabetes technology have led to ...

For initial treatment of eosinophilic esophagitis (EoE), an elimination diet is the most cost-effective option from a payer perspective and proton pump inhibitor (PPI) therapy is more cost-effective ...

Multicancer early detection testing results in extended life-years and reduced cancer treatment costs through earlier diagnosis, leading to a cost-effective option in cancer screening. Objectives: ...

A certain type of bariatric surgery may prove more cost-effective over time than a popular weight loss drug, an economic evaluation study suggested. In an analysis of adults with class II obesity (BMI ...

Researchers have found the CAR-T cell therapy Breyanzi (lisocabtagene maraleucel) to be a cost-effective second-line treatment for patients with relapsed and refractory diffuse large B-cell lymphoma ...